Form 4: ALXO CEO Acquires 597,500 Stock Options

ALX Oncology Holdings Inc. CEO Jason Lettmann acquired 597,500 employee stock options with an exercise price of $1.70.

Summary

• Jason Lettmann, Chief Executive Officer and Director of ALX Oncology Holdings Inc. (ALXO), acquired 597,500 employee stock options.
• The options have an exercise price of $1.70 per share.
• The transaction date for the option grant was October 14, 2025.
• The options are set to expire on October 14, 2035.
• The vesting schedule for these options is split: one-third will vest on April 30, 2026, and the remaining two-thirds will vest on October 31, 2026.
• Following this transaction, Mr. Lettmann directly beneficially owns 597,500 derivative securities.

Sentiment

Score: 7

Explanation: The acquisition of a substantial number of stock options by the CEO is generally viewed positively as it aligns management's financial interests with the long-term performance of the company's stock, incentivizing value creation for shareholders.

Positives

• The acquisition of a significant number of stock options by the CEO indicates a strong alignment of management's interests with long-term shareholder value creation.
• The long expiration date of October 14, 2035, provides a substantial window for the company's stock price to appreciate, potentially benefiting both the CEO and shareholders.

Risks

• The value of the acquired stock options is entirely contingent on ALX Oncology's stock price exceeding the $1.70 exercise price in the future.
• Adverse market conditions or company-specific operational setbacks could negatively impact the stock price, potentially rendering the options worthless.

Future Outlook

The defined vesting schedule for the options in 2026 establishes a forward-looking incentive structure for the CEO, directly linking his compensation to future company performance. The extended expiration date provides a significant runway for potential value creation.

Industry Context

The granting of stock options is a prevalent compensation strategy within the biotechnology and pharmaceutical sectors, designed to attract and retain executive talent. This practice aligns executive incentives with long-term shareholder value, which is particularly relevant given the often protracted development cycles for new therapeutic products in these industries.

Comparison to Industry Standards

• Granting stock options to executive leadership is a standard compensation practice across the biotechnology and broader corporate landscape, comparable to practices at companies like Amgen, Gilead Sciences, or Regeneron Pharmaceuticals.
• The specific number of options (597,500) and the exercise price ($1.70) would need to be benchmarked against peer companies of similar market capitalization and stage of development to assess if it falls within typical ranges for a CEO.
• The vesting schedule (one-third in April 2026, two-thirds in October 2026) is a relatively short-term vesting compared to typical multi-year annual grants, but it could be part of an initial grant or a specific performance-based award.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of the CEO's interests with long-term shareholder value.
• Employees: No direct impact mentioned, but executive compensation practices can influence overall company culture and morale.

Next Steps

• Monitor ALX Oncology's stock performance relative to the $1.70 exercise price.
• Observe future SEC filings for additional insider transactions by Mr. Lettmann or other executives.
• Track the company's operational and financial results leading up to the option vesting dates in 2026.

Key Dates

Keywords

ALX Oncology Holdings Inc., ALXO, Jason Lettmann, Stock Options, CEO, Insider Transaction, Equity Compensation, Form 4, Biotechnology, Oncology